241 related articles for article (PubMed ID: 20979564)
1. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
Swart JF; Barug D; Möhlmann M; Wulffraat NM
Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
[TBL] [Abstract][Full Text] [Related]
2. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
3. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
Nigrovic PA; Mannion M; Prince FH; Zeft A; Rabinovich CE; van Rossum MA; Cortis E; Pardeo M; Miettunen PM; Janow G; Birmingham J; Eggebeen A; Janssen E; Shulman AI; Son MB; Hong S; Jones K; Ilowite NT; Cron RQ; Higgins GC
Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
5. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA).
Ohlsson V; Baildam E; Foster H; Jandial S; Pain C; Strike H; Ramanan AV
Rheumatology (Oxford); 2008 Apr; 47(4):555-6. PubMed ID: 18321945
[No Abstract] [Full Text] [Related]
6. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease.
Woo P
Ann Rheum Dis; 2008 Mar; 67(3):281-2. PubMed ID: 18292104
[No Abstract] [Full Text] [Related]
7. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
Verbsky JW; White AJ
J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series.
Record JL; Beukelman T; Cron RQ
J Rheumatol; 2011 Jan; 38(1):180-1. PubMed ID: 21196588
[No Abstract] [Full Text] [Related]
9. [New treatments for idiopathic juvenile arthritis].
Bader-Meunier B; Quartier P
Arch Pediatr; 2009 Dec; 16(12):1607-11. PubMed ID: 19896351
[TBL] [Abstract][Full Text] [Related]
10. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
Cohen SB
Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
[TBL] [Abstract][Full Text] [Related]
12. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis.
Mirkinson LJ; Nagle D; Kadom N; Jones OY
J Clin Rheumatol; 2006 Apr; 12(2):83-6. PubMed ID: 16601542
[TBL] [Abstract][Full Text] [Related]
13. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
[TBL] [Abstract][Full Text] [Related]
14. A case of macrophage activation syndrome successfully treated with anakinra.
Kelly A; Ramanan AV
Nat Clin Pract Rheumatol; 2008 Nov; 4(11):615-20. PubMed ID: 18825135
[TBL] [Abstract][Full Text] [Related]
15. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
[TBL] [Abstract][Full Text] [Related]
16. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.
Karanikolas G; Charalambopoulos D; Vaiopoulos G; Andrianakos A; Rapti A; Karras D; Kaskani E; Sfikakis PP
Rheumatology (Oxford); 2008 Sep; 47(9):1384-8. PubMed ID: 18603660
[TBL] [Abstract][Full Text] [Related]
18. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
19. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids.
Bruck N; Suttorp M; Kabus M; Heubner G; Gahr M; Pessler F
J Clin Rheumatol; 2011 Jan; 17(1):23-7. PubMed ID: 21169853
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases.
Botsios C; Sfriso P; Ostuni PA; Todesco S; Punzi L
Rheumatology (Oxford); 2007 Jun; 46(6):1042-3. PubMed ID: 17449489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
